Navigation Links
A Collaboration to Find New Tools to Fight Leukemia

Mayo Clinic Cancer Center, working in collaboration with Ohio State University Comprehensive Cancer Center//, presented evidence Sunday that a novel regimen of three chemotherapy drugs, pentostatin, cyclophosphamide and rituximab, resulted in significant clinical response in patients with previously untreated chronic lymphocytic leukemia (CLL). Lead researcher and Mayo Clinic hematologist Neil E. Kay, M.D., presented these findings at the 2006 American Society of Hematology Annual Meeting in Orlando.

“Chronic lymphocytic leukemia is incurable, but continues to be made more manageable with the advent of powerful new chemoimmunotherapy tools,” says Dr. Kay. “We and our collaborators at Ohio State University, in particular Dr. Michael Grever, have done previous research on pentostatin that led us to believe there would be success with this regimen, and are pleased with the results.”

Regimens using rituximab are common for CLL patients, says Dr. Kay, and his team decided to build upon that knowledge and their understanding of the highly potent chemotherapeutic antibiotic pentostatin to try to develop an even better treatment option. The investigators initiated a trial of three weeks (one cycle) of combined chemotherapy drugs pentostatin (P), cyclophosphamide (C) and rituximab (R) repeated in six cycles for 64 symptomatic but previously untreated patients. Patients in the study also received one year of prophylactic sulfamethoxazole-trimethoprim (anti-infection drug) and acyclovir (antiviral drug) along with the PCR treatment.

The researchers reviewed study participants’ prognostic status and divided the patients into risk categories at the beginning of the study, using a number of different prognostic evaluation tools to describe them, including the Rai stages (clinical levels of disease progression), CD38 and ZAP-70 (overexpressed proteins found in CLL cells), IgVH (mutational status of the immunoglobulin gene occurring in CLL patien ts), and FISH panel assessments (fluorescent probes on the chromosomes to determine common recurring genetic mutations in CLL). The majority of the patients were in high-risk categories; they had significant disease progression and/or a high expectation of rapid advancement of disease.

Following treatment, Dr. Kay’s team found that 91 percent of the patients experienced positive clinical responses (experienced improvement in their condition) to the treatment based on the National Cancer Institute’s Working Group criteria for responses. Forty-one percent achieved complete response, 22 percent experienced nodular partial response and 28 percent partial response, with the average patient’s disease currently estimated to being in response for 32.6 months. The researchers also found that bone marrow suppression and/or infections were minimal.

The prognostic variables that normally indicate likelihood of poor response to treatment appeared to be negated by the treatment --only one genetic defect (deletion of the p arm of chromosome 17) was found to prevent complete response or nodular partial response; the other risk factors did not diminish treatment effectiveness. Also, the researchers found that the regimen was equally effective in young and elderly (over age 70) patients.

“We are very pleased with the results of this study,” says Dr. Kay. “This is a new, viable option for high-risk patients who might not have had much hope before, and it’s especially exciting that it works for patients of all age groups.”

Chronic lymphocytic leukemia is a blood and bone marrow cancer that affects 10,000 new patients each year in the United States. It is called chronic leukemia because it progresses more slowly than acute leukemia, and lymphocytic because it affects a group of white blood cells (lymphocytes), an important component of the immune system which typically fights infection.

Source-Newwise
SRM
'"/>




Related medicine news :

1. Collaborations planned between British Organization and Indian health care industry
2. Crusade Against Cancer: Collaborations On The Anvil
3. Mayo Clinic and Indian Health Service Form Clinical Practice Collaboration
4. International Collaboration Takes Aim at Rabies
5. British Medical Association Plans Collaboration With India
6. British Medical Association Plans Collaboration With India
7. LondonMet Keen on Widening Research Collaborations With India
8. New Tools To Identify Flu Strains
9. Is There a Connection between Hearing loss and High-speed Dental Tools?
10. Software Tools & Fonts in Seven Indian Languages
11. ‘Dirty’ and Dangerous Tools Put Full Stop to Operatin
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2018)... FRANCISCO (PRWEB) , ... September 24, 2018 , ... On ... Properties (NYSE: BXP), will host Runyon Up, a stair climb at the new Salesforce ... Cancer survivors, their friends, family members and colleagues are expected to take part in ...
(Date:9/24/2018)... ... September 24, 2018 , ... Paris-based My ... customers’ doorsteps. Its roster of talented chefs works constantly to create innovative, balanced ... In addition to its standard weekly meals, My Cuistot is happy to customize ...
(Date:9/22/2018)... ... September 21, 2018 , ... From 1991 to 2012, Works of ... Carolina’s programs and clients, all thanks to the generous artists, sponsors, and patrons who ... 1991—about HIV/AIDS, about community response to HIV/AIDS, about the Alliance of AIDS Services - ...
(Date:9/22/2018)... ... September 22, 2018 , ... The health risks associated with ... risk that particularly affects older adults – the risk of injury due to falling. ... the day and adult aged 65 and older falls in the United States. Every ...
(Date:9/15/2018)... ... September 14, 2018 , ... Today, Mediaplanet announces the launch ... work being done within rare diseases research, diagnostics, and will highlight what industry ... diseases. , Clay Matthews, Super Bowl-winning linebacker for the Green ...
Breaking Medicine News(10 mins):
(Date:9/15/2018)... , ... September 14, 2018 , ... ... the launch of “Carto.graph”. Developed in collaboration with SmithGroup, the Carto.graph collection is ... landscape. , EnviroLeather™ teamed up with SmithGroup’s healthcare interior designer, Aileen Avila-Banaag ...
(Date:9/13/2018)... ASTORIA, N.Y. (PRWEB) , ... September 13, 2018 , ... ... now open. Located at 31-57 31st St., the new arrival is called Form50 ... machine created by Sebastien Lagree called The Megaformer™ - a hybrid Pilates reformer with ...
(Date:9/13/2018)... U.K. (PRWEB) , ... September ... ... (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and ... the Company’s first candidate product. , The U.S. Food and Drug Administration ...
Breaking Medicine Technology: